A summary of published research, with citations. It states no amount, schedule or route, and makes no claim about what this compound does in a person. Supplied for laboratory research use only.
On this page · 9 sections
- Where does the name TB-500 come from?
- What is thymosin beta-4, the protein it comes from?
- Why residues 17 to 23?
- What has TB-500 itself been tested in?
- What did the full protein reach in clinical trials?
- What is TB-500's regulatory status?
- What is TB-500 commonly confused with?
- How can a researcher tell which molecule is in the vial?
- Frequently asked questions
TB-500 is a trade name, not a scientific one. Analysed by anti-doping laboratories, the material sold under it was identified as Ac-LKKTETQ: the N-terminally acetylated residues 17 to 23 of thymosin beta-4, a 43-amino-acid actin-binding protein found in most cells. Seven residues of forty-three. Almost all the well-known research, including the cardiac and wound studies and the human trials, used the full protein. The fragment itself has a few cell and rodent studies, no completed human trial, and no approval anywhere.

Where does the name TB-500 come from?
Not from a laboratory or a drug company's development pipeline. Ho and colleagues at the Hong Kong Jockey Club describe TB-500 as "a veterinary preparation", containing a synthetic version of the peptide LKKTETQ with an artificial acetyl group on its N-terminus, that had emerged in equine sport (PMID 23084823). They developed a method to detect the acetylated peptide and its breakdown products in horse plasma and urine, because racing authorities needed to be able to prove its use.
In human sport the same question arose. Esposito and colleagues, working in a doping-control laboratory in Ghent, analysed a TB-500 product by high-resolution mass spectrometry and identified the acetylated 17-23 fragment of human thymosin beta-4 in it, then synthesised the fragment to confirm the identification (PMID 22962027).
So the first rigorous descriptions of what TB-500 is come from people trying to catch it, not from people developing it. That is unusual, and it explains why the name has no fixed definition. Some sellers use "TB-500" for the fragment, some for full-length thymosin beta-4, and some print the fragment's sequence beside the full protein's molecular weight. Why that matters for a certificate is covered in TB-500 vs thymosin beta-4.
What is thymosin beta-4, the protein it comes from?
Thymosin beta-4 was isolated from calf thymus as part of a mixture called thymosin fraction 5, at a time when the thymosins were thought of as thymic hormones. Low, Hu and Goldstein sequenced it in 1981: 43 amino acids, a molecular weight of 4,982 and an acetyl-blocked N-terminus (PMID 6940133).
Its real job turned out to have little to do with the thymus. In 1991 Safer and colleagues showed that thymosin beta-4 was identical to "Fx", the peptide that holds most of the unpolymerised actin in resting platelets. It forms a 1:1 complex with actin monomers and stops them polymerising (PMID 1999398). Its wide distribution and high concentration inside cells pointed to a general role in regulating the actin cytoskeleton, which is what cells use to change shape and move.
That is the thread connecting it to repair research. Cell migration depends on controlled actin assembly, and a protein that controls the free actin pool is a natural candidate for affecting how cells reach a wound.
| Thymosin beta-4 | TB-500 (as identified) | |
|---|---|---|
| What it is | Native protein, present in most cells | Synthetic fragment |
| Length | 43 amino acids | 7 amino acids, LKKTETQ |
| Ends | Acetylated N-terminus | Acetyl group added to the fragment's N-terminus |
| Molecular weight | 4,982 | Under 1,000 |
| Function shown | Sequesters G-actin 1:1 | Contains the central actin-binding motif |
| Human trials | Several phase 2 and 3 trials in wound and eye conditions | No completed trial |
| Approval | None | None |
Why residues 17 to 23?
Because that stretch is where thymosin beta-4's actin binding sits. A 2010 review by Sosne and colleagues maps the protein's active sites: an N-terminal four-residue fragment, Ac-SDKP, associated with reduced inflammation and fibrosis; an N-terminal fifteen-residue segment associated with cell survival; and the central actin-binding domain, residues 17 to 23, which in a short peptide was associated with cell migration, angiogenesis and wound closure in experimental systems (PMID 20179146). Several other activities had been described for the protein without being localised to any part of it.
That is the scientific rationale for the fragment, and it shows the limit. A short sequence that carries one site carries only that site. Activities mapped to other regions, or not yet mapped, cannot be assumed to come along with residues 17 to 23.
What has TB-500 itself been tested in?
Very little, and the most direct study is a cautionary one.
In 2024 Rahaman and colleagues set out to characterise TB-500 itself. They noted that the biological effects of the acetylated fragment "have not been documented", since earlier activity data concerned the unacetylated sequence. They followed its breakdown in human serum, in enzyme systems and in rats, and found that it was cut quickly: Ac-LK was the main metabolite in the first six hours, and Ac-LKK was detectable for up to 72 hours. In a fibroblast wound-closure assay, only one metabolite, Ac-LKKTE, showed a significant effect compared with control. The authors suggested that wound-healing activity previously attributed to TB-500 might belong to that metabolite rather than to the parent peptide (PMID 38382158).
That is one cell-culture and rat study, and it does not settle the question. It does show how little is known about the molecule that is actually sold: what reaches tissue, in what form and for how long.
What did the full protein reach in clinical trials?
Thymosin beta-4 got further than almost any compound in a research catalogue, and none of it transfers automatically to the fragment.
- Chronic wounds. RegeneRx ran phase 2 trials in venous stasis ulcers and pressure ulcers (NCT00832091, NCT00382174). In the venous ulcer trial, 73 patients at eight European sites were randomised. Safety was comparable to placebo, and the authors described the efficacy findings as suggesting potential rather than demonstrating it (PMID 20536470).
- Dry eye. A phase 2 trial of a thymosin beta-4 formulation for the eye, RGN-259, enrolled nine patients with severe dry eye and reported improvements in symptom and sign scores against vehicle (PMID 25826322). Larger phase 3 programmes, ARISE-1 to ARISE-3, followed and are listed as completed on ClinicalTrials.gov.
- Heart. The cardiac literature, including a 2004 Nature paper in mouse infarction models, used the full protein. It is covered in TB-500 and cardiac research.
None of these programmes produced an approved medicine. And every one of them tested the 43-residue protein, not Ac-LKKTETQ.
What is TB-500's regulatory status?
- Not approved anywhere. Neither TB-500 nor thymosin beta-4 has approval from Health Canada, the FDA or the EMA for any indication.
- US compounding. The FDA lists "thymosin beta-4, fragment (LKKTETQ), also known as TB-500" among bulk substances nominated for compounding that may present significant safety risks. It states that it has not identified any human exposure data for drug products containing the fragment.
- Sport. Thymosin beta-4 and TB-500 fall under section S2 of the World Anti-Doping Agency's Prohibited List, and detection methods exist for both humans and horses. See are peptides banned in sport.
- Canada. Not an authorised drug. Sold here as a research chemical for laboratory use only.
What is TB-500 commonly confused with?
Thymosin beta-4. The confusion the rest of this page is about. Evidence about the protein is not evidence about the fragment.
Thymosin Alpha-1. A different, unrelated 28-residue peptide from the same historical thymus fraction, with an immune-signalling literature and a licence in several countries. See what is Thymosin Alpha-1.
Ac-SDKP. Another natural fragment of thymosin beta-4, the first four residues at its N-terminus, with its own anti-fibrotic literature. It is not TB-500.
BPC-157. Sold beside TB-500 constantly, but unrelated in origin and mechanism. See BPC-157 vs TB-500 and what is BPC-157. Blends containing both are examined in Wolverine Stack vs GLOW and inside the KLOW blend.
How can a researcher tell which molecule is in the vial?
By mass, not by label. A seven-residue fragment and a 43-residue protein differ in molecular weight by more than a factor of five, so mass spectrometry tells them apart unambiguously. HPLC purity alone cannot, because a pure sample of the wrong molecule still reads as pure. What each method can and cannot see is set out in HPLC vs LC-MS.
Nothing here is medical, dosing, or therapeutic guidance.
Supplied here for laboratory use: TB-500. The laboratory's certificate for each lot is linked from its product page. For laboratory research use only.
Frequently asked questions
Is TB-500 the same as thymosin beta-4? No. As identified by doping-control laboratories, TB-500 is the acetylated fragment LKKTETQ, residues 17 to 23 of the 43-residue protein. Some products labelled TB-500 contain the full protein instead, which is why the molecular mass on a certificate matters. Studies of the protein do not transfer automatically to the fragment.
Why is it called TB-500? The name has no published scientific origin. It appears in the literature as the name of a veterinary preparation found in equine sport, analysed by doping-control chemists in Hong Kong and Belgium. Neither the letters nor the number have a documented meaning, and the name is not a regulated designation, which is why a sequence and a measured mass matter more than the label.
Has TB-500 been tested in humans? Not in any completed trial. The human trials people cite, in chronic wounds, dry eye and cardiac indications, used full-length thymosin beta-4. The FDA states it has not identified human exposure data for drug products containing the fragment. A 2024 study noted that the acetylated fragment's own biological effects had not been documented.
Does TB-500 break down quickly? In a 2024 study it was rapidly cut into shorter fragments in human serum and in rats, with Ac-LK the main early metabolite and Ac-LKK detectable for up to 72 hours. Only the metabolite Ac-LKKTE showed activity in a fibroblast wound-closure assay. Those are laboratory findings, not human pharmacokinetics.
Is TB-500 banned in sport? Yes. Thymosin beta-4 and TB-500 are covered by section S2 of the World Anti-Doping Agency's Prohibited List, as growth factors and related substances, at all times. Doping-control laboratories have published methods for detecting the fragment and its metabolites in urine and plasma, in both people and horses.
Selected Research References
- Esposito S, Deventer K, Goeman J, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Testing and Analysis. 2012;4(9):733-738. pubmed.ncbi.nlm.nih.gov/22962027
- Ho EN, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography-mass spectrometry. Journal of Chromatography A. 2012;1265:57-69. pubmed.ncbi.nlm.nih.gov/23084823
- Low TL, Hu SK, Goldstein AL. Complete amino acid sequence of bovine thymosin beta 4: a thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations. Proceedings of the National Academy of Sciences of the USA. 1981;78(2):1162-1166. pubmed.ncbi.nlm.nih.gov/6940133
- Safer D, Elzinga M, Nachmias VT. Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. Journal of Biological Chemistry. 1991;266(7):4029-4032. pubmed.ncbi.nlm.nih.gov/1999398
- Sosne G, Qiu P, Goldstein AL, Wheater M. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB Journal. 2010;24(7):2144-2151. pubmed.ncbi.nlm.nih.gov/20179146
- Rahaman KA, Muresan AR, Min H, et al. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. Journal of Chromatography B. 2024;1235:124033. pubmed.ncbi.nlm.nih.gov/38382158
- Guarnera G, DeRosa A, Camerini R, et al. The effect of thymosin treatment of venous ulcers. Annals of the New York Academy of Sciences. 2010;1194:207-212. pubmed.ncbi.nlm.nih.gov/20536470
- Sosne G, Dunn SP, Kim C. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015;34(5):491-496. pubmed.ncbi.nlm.nih.gov/25826322
All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.
